Skip to content

US · TAOX · BIOTECHNOLOGY

TAO Synergies Inc. (TAOX) intrinsic value and stock valuation

$1.55as of 2026-11-21 · Mkt cap 26.08M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TAO Synergies Inc. DCF and intrinsic value

InvestorsCraft values TAOX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TAOX’s statements →

TAO Synergies Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10036 taosynergies.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$300K
20212025
Net income
-$-28.74M
20212025
Free cash flow
-$-6.4M
20212025
Total equity
$21.9M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$300K$0.00$0.00$0.00$0.00
Operating income-$-9.05M-$-6.81M-$-8.31M-$-16.13M-$-12.62M
Net income-$-28.74M-$-12.77M-$-6.04M-$-5.57M-$-12.61M
EPSd-$-8.71M-$-10.38M-$-12.85M-$-19.89M-$-63.05M
Operating cash flow-$-6.4M-$-4.88M-$-5.17M-$-11.21M-$-8.71M
Capital expenditure$0.00$0.00-$0.00-$-10K-$0.00
Free cash flow-$-6.4M-$-4.88M-$-5.18M-$-11.22M-$-8.71M
Total assets$25.8M$17.7M$31.1M$38.6M$35.5M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.5M-$-17.66M-$-28.66M-$-37.48M-$-34.21M
Total equity$21.9M$6.78M$25.6M$35.4M$33.5M
Cash and short-term investments$5.5M$17.7M$30.1M$37.5M$34.2M
Income statement
20252024202320222021
Revenue$300K$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$300K$0.00$0.00$0.00$0.00
Research and development expenses$320K$1.6M$1.97M$6.32M$4.34M
Selling, general and administrative expenses$9.02M$5.21M$6.34M$9.81M$8.28M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$9.35M$6.81M$8.31M$16.1M$12.6M
Cost and expenses$9.35M$6.81M$8.31M$16.1M$12.6M
Interest income$440K$1.28M$1.65M$340K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$10K$10K$10K$0.00
Ebitda-$-9.04M-$-6.81M-$-8.31M-$-16.13M-$-12.61M
Operating income-$-9.05M-$-6.81M-$-8.31M-$-16.13M-$-12.62M
Total other income/expenses, net-$-19.69M-$-12.77M-$-6.04M-$-5.57M-$-12.61M
Income before tax-$-28.74M-$-12.77M-$-6.04M-$-5.57M-$-12.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-28.74M-$-12.77M-$-6.04M-$-5.57M-$-12.61M
Weighted average shares outstanding$3.3M$1.23M$470K$280K$200K
Weighted average diluted shares outstanding$3.3M$1.23M$470K$280K$200K
Balance sheet
20252024202320222021
Cash and short-term investments$5.5M$17.7M$30.1M$37.5M$34.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$25.4M$17.7M$30.5M$38.6M$35.5M
Property, plant and equipment, net$10K$10K$20K$20K$20K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$450K$0.00$560K$0.00$0.00
Total non-current assets$460K$10K$580K$20K$20K
Total assets$25.8M$17.7M$31.1M$38.6M$35.5M
Accounts payable$1.18M$320K$440K$660K$1.3M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.81M$1.01M$4.28M$1.31M$1.99M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.12M$9.94M$1.25M$1.88M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$3.94M$11M$5.53M$3.19M$1.99M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-76.2M-$-47.17M-$-33.61M-$-19.83M-$-14.14M
Accumulated other comprehensive income (loss)$10K$10K$0.00$0.00$0.00
Total equity$21.9M$6.78M$25.6M$35.4M$33.5M
Total investments$450K$0.00$2M$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.5M-$-17.66M-$-28.66M-$-37.48M-$-34.21M
Cash flow statement
20252024202320222021
Net income-$-28.74M-$-12.77M-$-6.04M-$-5.57M-$-12.61M
Depreciation and amortization$0.00$10K$10K$10K$0.00
Stock-based compensation$1.39M$30K$1.01M$3.74M$3.28M
Change in working capital$420K$500K$360K-$-610K$30K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$860K-$-130K-$-220K-$-640K$40K
Net cash provided by operating activities-$-6.4M-$-4.88M-$-5.17M-$-11.21M-$-8.71M
Investments in property, plant and equipment$0.00$0.00-$0.00-$-10K-$0.00
Acquisitions, net-$-750K$0.00-$-560K$0.00$0.00
Net cash used for investing activities-$-28.89M-$-1M-$-2M-$-10K-$0.00
Common stock issued$9.96M$0.00$0.00$13.9M$23.8M
Common stock repurchased-$-1.43M$0.00$0.00$0.00$0.00
Dividends paid-$-260K-$-950K-$-640K$0.00$0.00
Net cash used for financing activities$23.1M-$-5.12M-$-1.64M$14.5M$37.1M
Net change in cash-$-12.16M-$-11.01M-$-8.82M$3.26M$28.4M
Cash at end of period$5.5M$17.7M$28.7M$37.5M$34.2M
Operating cash flow-$-6.4M-$-4.88M-$-5.17M-$-11.21M-$-8.71M
Capital expenditure$0.00$0.00-$0.00-$-10K-$0.00
Free cash flow-$-6.4M-$-4.88M-$-5.18M-$-11.22M-$-8.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TAO Synergies Inc.

        TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

        CEO
        Joshua N. Silverman
        Employees
        4
        Beta
        1.43

        Explore

        Frequently asked questions

        What is the intrinsic value of TAO Synergies Inc. (TAOX)?

        InvestorsCraft does not currently publish an intrinsic value for TAOX. How the IC value is calculated.

        Is TAOX undervalued?

        InvestorsCraft does not publish an undervaluation signal for TAOX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.